

The Trust. The Truth.

June 17, 2021

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

BSE Limited Phiroze Jeejeeboy Towers Dalal Street, Mumbai- 400 001

Dear Sirs.

Sub: News Clarification

This is with reference to your letter dated 17 June 2021 bearing reference no. NSE/CM/Surveillance/10880 in relation to the recent news item which appeared on the website www.moneycontrol.com dated 17 June 2021 captioned "PharmEasy in talks to buy Thyrocare in deal worth around Rs 7,000 crore".

In this regard, the Company would like to provide the following clarification:

The Company during its normal course of business keeps exploring various opportunities to enhance shareholder value.

The Company is not aware of any information which is required to be disclosed under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and which has not already been disclosed to the stock exchanges.

All the material information, that may have a bearing on the operation/performance of the Company which includes all price sensitive information under Regulation 30 of the Listing Regulations, has always been disclosed by the Company in accordance with the Listing Regulations (including within the prescribed time period). Further, we shall keep the stock exchanges informed in case of any specific developments and the Company shall ensure full compliance with its obligations under Regulation 30 of the Listing Regulations in the future as well.

We trust the above clarifies and request you to kindly take the same on record.



Thyrocare Technologies Limited



We regret that there was some delay in sending the reply due to some problems with our System.

Thanking you,

Yours faithfully, For **Thyrocare Technologies Limited**,

Ramjee Dorai

Company Secretary and Compliance Officer

